Search for "this compound" in Full Text gives 512 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2019, 15, 2003–2012, doi:10.3762/bjoc.15.196
Graphical Abstract
Figure 1: Withanolides from Physalis peruviana. A) Structures of the newly characterised truncated withanolid...
Figure 2: Key NMR correlations. (A) COSY and HMBC correlations for irinan A (2). (B) COSY and HMBC correlatio...
Figure 3: Structures and biosynthesis of androstanes. (A) Androstane backbone and androsterone (7) as a typic...
Figure 4: Intrinsic reactivity of 4ß-hydroxywithanolide E (1) under acidic/basic and oxidative conditions, re...
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2019, 15, 1705–1711, doi:10.3762/bjoc.15.166
Graphical Abstract
Scheme 1: Chemical structures of host-1, host-2, G1, and G2.
Figure 1: 1H NMR spectra of G1 (1.0 mmol, D2O, pD = 2.0) in the presence of host-1 at different concentration...
Figure 2: 1H NMR spectra of G1 (1.0 mmol, D2O, pD = 2.0) in the presence of host-2 at different concentration...
Scheme 2: Plausible diastereomers showing the fluorescence response of G2 with host-1.
Figure 3: Fluorescence spectral changes of G2 (10.0 μM) in the presence of host-1 (a) and host-2 (b) at diffe...
Figure 4: 1H NMR spectra of G2 (1.0 mmol, D2O, pD = 2.0) in the presence of different concentrations of host-1...
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 1491–1504, doi:10.3762/bjoc.15.151
Graphical Abstract
Figure 1: Allenes 1a–j used in this study.
Scheme 1: Transformations of allene 1g in TfOH leading to the formation of cations E1, E2 and E4 including se...
Figure 2: 31P NMR monitoring of the progress of transformation of E1 into E2 and E4 in TfOH at room temperatu...
Scheme 2: Results of the hydrolysis of cations A–H.
Scheme 3: Preparation of amides 6a,b from cations A, B, and F–H.
Scheme 4: Large-scale one-pot solvent-free synthesis of amides 6a,b from the corresponding propargylic alcoho...
Scheme 5: AlCl3-promoted hydroarylation of allene 1b by benzene leading to alkene Z-11n.
Scheme 6: Reaction of allene 1a with benzene under the action of AlCl3 followed by quenching of the reaction ...
Scheme 7: Multigram-scale one-pot synthesis of indane 12d from 2-methylbut-3-yn-2-ol.
Figure 3: NMR spectra of starting allene 1a (black) and its complex with 1 equivalent of AlCl3 13 (red) in CD2...
Scheme 8: 1H, 13C, and 31P NMR monitoring of AlCl3-promoted reactions of allene 1a leading to compounds E-14 ...
Scheme 9: Plausible reaction mechanism A for the formation of compounds 9, 10, 11, 12 from aillene 1a involvi...
Scheme 10: Plausible reaction mechanism B of formation of compounds 11, 12 from allene 1a involving HCl–AlCl3 ...
Figure 4: Visualization of LUMO, only positive values are shown, isosurface value 0.043: (a) species 16, (b) ...
Beilstein J. Org. Chem. 2019, 15, 1480–1484, doi:10.3762/bjoc.15.149
Graphical Abstract
Scheme 1: Reaction of ketone 1 with electron-deficient alkenes 2.
Scheme 2: Reactions of ester 4 and amide 5 with electron-deficient alkenes 6.
Figure 1: Single crystal X-ray structure for 7c.
Scheme 3: Reactions of ester 4 and amide 5 with N-methylmaleimide.
Figure 2: Single crystal X-ray structure for 9.
Scheme 4: Reduction and oxidation of adducts 9 and 10.
Scheme 5: Formation of amides 15a and 15b and Suzuki–Miyaura coupling to yield 16.
Beilstein J. Org. Chem. 2019, 15, 1339–1346, doi:10.3762/bjoc.15.133
Graphical Abstract
Scheme 1: CTV and chiral CTV derivatives.
Scheme 2: The two enantiomeric crown isomers of chiral CTV 1 and its saddle isomer 1-S.
Scheme 3: Synthesis of CTV 1.
Figure 1: a) Chromatogram of an analytical separation of (rac)-1 on a CHIRALPAK IB column as the stationary p...
Figure 2: a) Chromatogram of the analytical separation of (rac)-1 (CHIRALPAK IB, 100% MeOH, 293 K, flow rate:...
Figure 3: a) 1H NMR spectrum of the neat crown isomers of (rac)-1 in CD3OD (400 MHz, 298 K); b) 1H NMR spectr...
Figure 4: Chromatograms of the analytical separations (CHIRALPAK IB, acetonitrile/water 40:60, 293 K, flow ra...
Figure 5: The mole fractions obtained in the racemization experiment plotted against the time, with black tri...
Beilstein J. Org. Chem. 2019, 15, 1331–1338, doi:10.3762/bjoc.15.132
Graphical Abstract
Figure 1: Interactions of a pair of dipolar rotors in different orientations. The axes of the rotors are para...
Figure 2: Structures of molecular dipolar rotors/linker molecules 1–5.
Scheme 1: General synthetic strategy to prepare the dipolar rotors 1–5.
Scheme 2: Synthesis of 3,3'-(2,3-difluoro-1,4-phenylene)dipropiolic acid (1) starting with diiodination of 1,...
Scheme 3: Synthesis of 3,3'-(5,6-Difluoro-2,1,3-benzothiadiazol-4,7-diyl)dipropiolic acid (2) and 3,3'-(5,6-D...
Scheme 4: Synthesis of 3,3'-(5,6-dicyano-1,3-benzodioxole-4,7-diyl)dipropiolic acid (4) and 3,3'-(6,7-dicyano...
Beilstein J. Org. Chem. 2019, 15, 1298–1303, doi:10.3762/bjoc.15.128
Graphical Abstract
Figure 1: A) Organization of the micacocidin-type gene cluster from Massilia sp. NR 4-1 (top) and of the mic ...
Figure 2: Structures of massiliachelin (1), agrochelin (2), micacocidin (3), pyochelin I (4), pyochelin II (5...
Beilstein J. Org. Chem. 2019, 15, 1236–1256, doi:10.3762/bjoc.15.121
Graphical Abstract
Figure 1: Structures of natural steroids of A) animal and B) plant origin.
Scheme 1: Synthesis of a steroidal β-lactam by Ugi reaction of a cholanic aldehyde [14].
Scheme 2: Synthetic route to steroidal 2,5-diketopiperazines based on a diastereoselective Ugi-4CR with an an...
Scheme 3: Multicomponent synthesis of a heterocycle–steroid hybrid using a ketosteroid as carbonyl component [18]....
Scheme 4: Synthesis of peptidomimetic–steroid hybrids using the Ugi-4CR with spirostanic amines and carboxyli...
Scheme 5: Synthesis of azasteroids using the Ugi-4CR with androstanic and pregnanic carboxylic acids [22].
Figure 2: Ugi-4CR-derived library of androstanic azasteroids with diverse substitution patterns at the phenyl...
Scheme 6: Synthesis of 4-azacholestanes by an intramolecular Ugi-4C-3R [26].
Scheme 7: Synthesis of amino acid–steroid hybrid by multiple Ugi-4CR using steroidal isocyanides [29].
Scheme 8: Synthesis of ecdysteroid derivatives by Ugi-4CR using a steroidal isocyanide [30].
Scheme 9: Stereoselective multicomponent synthesis of a steroid–tetrahydropyridine hybrid using a chiral bifu...
Scheme 10: Pd(II)-catalyzed three-component reaction with an alkynyl seco-cholestane [34].
Scheme 11: Multicomponent synthesis of steroid–thiazole hybrids from a steroidal ketone [36].
Scheme 12: Synthesis of cholanic pseudo-peptide derivatives by novel MCRs based on the reactivity of ynamide [37,38].
Scheme 13: Synthesis of steroid-fused pyrimidines and pyrimidones using the Biginelli-3CR [39,42,43].
Scheme 14: Synthesis of steroidal pyridopyrimidines by a reaction sequence comprising a 4CR followed by a post...
Scheme 15: Synthesis of steroid-fused pyrimidines by MCR of 2-hydroxymethylene-3-ketosteroids [46].
Scheme 16: Synthesis of steroid-fused naphthoquinolines by the Kozlov–Wang MCR using ketosteroids [50,51].
Scheme 17: Conjugation of steroids to carbohydrates and peptides by the Ugi-4CR [62,63].
Scheme 18: Solid-phase multicomponent conjugation of peptides to steroids by the Ugi-4CR [64].
Scheme 19: Solid-phase multicomponent conjugation of peptides to steroids by the Petasis-3CR [68].
Scheme 20: Synthesis of steroidal macrobicycles (cages) by multiple multicomponent macrocyclizations based on ...
Scheme 21: One-pot synthesis of steroidal cages by double Ugi-4CR-based macrocyclizations [76].
Beilstein J. Org. Chem. 2019, 15, 1032–1045, doi:10.3762/bjoc.15.101
Graphical Abstract
Figure 1: 2-Aminoimidazole alkaloids from marine sponges.
Figure 2: The Knoevenagel–Michael adduct [24] and expected products.
Scheme 1: The three component condensation of imidazo[1,2-a]pyridine, aldehydes and Meldrum’s acid described ...
Figure 3: Molecular structure of 1-([1,1'-biphenyl]-4-yl)-5-oxo-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-c]imidazo...
Scheme 2: Two forms of cation 9i.
Figure 4: Molecular structure of 3-(2-amino-4-phenyl-1H-imidazol-5-yl)-3-(p-tolyl)propanoic acid 11b accordin...
Scheme 3: Three forms of the compound 11b in the crystal phase.
Scheme 4: Synthesis of the mixture of compounds 13 and 14.
Figure 5: Molecular structure of aminoimidazo[1,2-c]pyrrole 16a according to X-ray diffraction data. Thermal ...
Scheme 5: Resonance structures of 16a.
Figure 6: 3,3’-Spirooxindole alkaloids.
Figure 7: Molecular structure of aminoimidazo[1,2-c]pyrrole 19a according to X-ray diffraction data. Thermal ...
Scheme 6: Resonance structures of 19a.
Beilstein J. Org. Chem. 2019, 15, 1008–1019, doi:10.3762/bjoc.15.99
Graphical Abstract
Figure 1: Total ion chromatograms of hexane extracts from the incubations of HcS with A) FPP, B) GPP and C) G...
Figure 2: Structures of HcS products arising A) from FPP together with related oxidation product 9, B) from G...
Scheme 1: Initial steps of the cyclisation of GPP towards monoterpene products [34]. Both pathways are likely co-...
Scheme 2: Late stage cyclisations of the himachalyl cation B to HcS products 1–6. Alternative mechanistic and...
Figure 3: EI mass spectrum of 1 arising from an incubation of (2-2H)GPP and IPP with FPPS and HcS showing a l...
Figure 4: Stereochemical course of the final deprotonation step towards 3, 5 and 6 investigated by GC–MS. EI ...
Scheme 3: Proposed cyclisation mechanism towards cation B via an initial 1,11-cyclisation (path A) and an hyp...
Figure 5: Total ion chromatogram of hexane extracts from HcS incubations with A) (R)-NPP, B) (S)-NPP and C) (...
Figure 6: The origin of the two diastereotopic methyl groups in 1. Partial 13C NMR spectrum of A) unlabelled 1...
Figure 7: Stereochemical course of the 1,11-cyclisation at C-1 for 7. Partial HSQC spectra of HcS incubation ...
Figure 8: Investigation of the 1,3-hydride shift in the cyclisation towards 1. Partial 13C NMR spectra of A) ...
Figure 9: Stereochemical course of the 1,3-hydride shift at C-10 in 1. Partial HSQC spectra of A) unlabelled 1...
Figure 10: Position specific mass shift analysis for selected EIMS ions of HcS products. Black dots represent ...
Beilstein J. Org. Chem. 2019, 15, 981–991, doi:10.3762/bjoc.15.96
Graphical Abstract
Figure 1: Bifunctional DAT as a cross-linker for proteins. The compound is a turn-on-probe, i.e., the fluores...
Scheme 1: Preparation of DAT–ALA conjugate 3 with fluorinated benzyl residue.
Scheme 2: Preparation of conjugate 7 consisting of fluorinated DAT and ALA moieties with an additional propyl...
Figure 2: High-resolution XPS of SAM 3.
Figure 3: High-resolution XPS of SAM 7.
Beilstein J. Org. Chem. 2019, 15, 937–946, doi:10.3762/bjoc.15.90
Graphical Abstract
Figure 1: Structure of the β-thiols 1a and 1b and of the commercial alkenes 2a and 2b.
Scheme 1: Synthesis of the n-alkyl thioglycosides 3–5, 7 and 8. Detailed reaction conditions are reported in ...
Scheme 2: Synthesis of the lipophilic scaffold 6; DMAP = N,N-dimethylaminopyridine.
Figure 2: Periodic monitoring by 1H NMR (300 MHz, DMF-d7) of the formation of product 8 from a mixture compou...
Figure 3: Micrographs of giant vesicles and lipid aggregates obtained from the gentle hydration (in PBS, pH 7...
Figure 4: A simplified (and not in scale) representation of the ELLA assay, to study the interaction between ...
Figure 5:
Inhibition curves for the binding of WGA-HRP to PAA-GlcNAc by D-GlcNAc The symbols (■), () and (○) ...
Figure 6: Main poses obtained from docking experiments. WGA (PDB 2UVO) surface is shown in white for monomer ...
Beilstein J. Org. Chem. 2019, 15, 795–800, doi:10.3762/bjoc.15.76
Graphical Abstract
Scheme 1: Reaction design.
Scheme 2: Scope of electrochemical synthesis of axially chiral biaryls. Reaction conditions: undivided cell, 2...
Scheme 3: Proposed reaction mechanism for the electrochemical synthesis of 3a.
Scheme 4: Computation investigation on the vinyl radical cyclization. DFT (M06-2X/6-31G*) calculated energeti...
Beilstein J. Org. Chem. 2019, 15, 733–745, doi:10.3762/bjoc.15.69
Graphical Abstract
Figure 1: Absorption spectra in the UV and visible spectral region: 1) bis(cyclopentadienyl)titan dichloride (...
Figure 2: Absorption spectra in the visible spectral region: 1) Cp2TiCl2·AlEt2Cl (toluene, 10 mmol/L, Ti/Al r...
Figure 3: 1Н NMR spectra of tricyclopentadiene (a) and the interaction product between Cp2TiCl2 and AlEt2Cl w...
Scheme 1: Mechanism of alkylation of Cp2TiCl2.
Figure 4: Visible spectra of a mixture of Cp2TiCl2 and AlEt2Cl as function of time.
Figure 5: Thermometric curve of DCPD polymerization using the catalyst system based on Cp2TiCl2 (a) and its s...
Scheme 2: The structures formed as a result of the cationic polymerization of dicyclopentadiene.
Scheme 3: The units resulting from ROMP of dicyclopentadiene.
Scheme 4: Mechanism of ROMP dicyclopentadiene.
Figure 6: FTIR spectrum of PDCPD obtained in toluene with the catalyst system based on Cp2TiCl2 and AlEt2Cl.
Figure 7: 1Н NMR spectrum of PDCPD obtained with the catalytic system based on Cp2TiCl2 and AlEt2Cl.
Figure 8: GPC traces for two samples of DCPD polymers obtained at a concentration of Cp2TiCl2/AlEt2Cl complex...
Figure 9: IR spectra of cationic polymerized dicyclopentadiene taken after certain periods of time exposed to...
Figure 10: Correlation of intensities of vibrational bands at 1620 and 700 cm−1 and layer exposure time in air...
Figure 11: DSC exotherm for PDCPD subjected to air oxidation for 700 hours.
Figure 12: DSC exotherm for PDCPD subjected to unexposed film: 1) in air atmosphere; 2) in argon.
Scheme 5: Possible radical formation in the reaction (1).
Scheme 6: The first step of the chain propagation.
Figure 13: Dependence of intensities of adsorption bands at 1410 and 700 cm−1 and dwell time of the layer in a...
Figure 14: Semi-logarithmic kinetic curve of PDCPD oxidation in air (thin layer on silicon) with respect to in...
Figure 15: The distribution of oxygen concentration in the polymer layer: 1 – a layer of oxidized cross-linked...
Figure 16: Dependence of the ratio of adsorption bands at 1700 and 700 cm−1 on the exposure time of the layer ...
Figure 17: Infrared spectra (a) of products of cationic polymerization of DCPD, stabilized with an antioxidant...
Beilstein J. Org. Chem. 2019, 15, 655–678, doi:10.3762/bjoc.15.61
Graphical Abstract
Scheme 1: Discovery of the LANCA three-component reaction. The reaction of pivalonitrile (1) with lithiated m...
Scheme 2: Proposed mechanism of the LANCA three-component reaction to β-ketoenamides KE and pyridin-4-ol deri...
Scheme 3: One-pot preparation of pyridin-4-ols PY and their subsequent transformations to highly substituted ...
Scheme 4: Synthesis of β-ketoenamides KE by the LANCA three-component reaction of alkoxyallenes, nitriles and...
Scheme 5: β-Ketoenamides KE36–43 derived from enantiopure components.
Scheme 6: Bis-β-ketoenamides KE44–46 derived from aromatic dicarboxylic acids.
Scheme 7: Conversion of alkyl propargyl ethers E into aryl-substituted β-ketoenamides KEAr and selected produ...
Scheme 8: Condensation of LANCA-derived β-ketoenamides KE with ammonium salts to give 5-alkoxy-substituted py...
Scheme 9: Synthesis of PM31–35 from β-ketoenamides KE37, KE38, KE40, KE41 and KE78 obtained by method A (NH4O...
Scheme 10: Synthesis of bis-pyrimidine derivatives PM36, PM39 and PM40 from β-ketoenamides KE44–46 by method A...
Scheme 11: Functionalization of pyrimidine derivatives PM through selenium dioxide oxidations of PM5, PM9, PM15...
Scheme 12: Conversion of 2-vinyl-substituted pyrimidine PM7 into aldehyde PM50; (NMO = N-methylmorpholine N-ox...
Scheme 13: Deprotection of 5-alkoxy-substituted pyrimidines PM2, PM20 and PM29 and conversion into nonaflates ...
Scheme 14: Palladium-catalyzed coupling reactions of PM54 and PM12 giving rise to new pyrimidine derivatives P...
Scheme 15: Synthesis of pyrimidyl-substituted pyridyl nonaflate PM60.
Scheme 16: Condensation of LANCA-derived β-ketoenamides KE with hydroxylamine hydrochloride leading to pyrimid...
Scheme 17: Reactions of β-ketoenamides KE15 and KE7 with hydroxylamine hydrochloride leading to pyrimidine N-o...
Scheme 18: Structures of pyrimidine N-oxides PO30–33 derived from β-ketoenamides KE43, KE45, KE78 and KE80.
Scheme 19: Reduction of PO4 to PM5 and Boekelheide rearrangements of PO13, PO14, PO4 and PO30 to 4-acetoxymeth...
Scheme 20: Deprotection of 4-acetoxymethyl-substituted pyrimidine derivatives PM61 and PM63, oxidations to for...
Scheme 21: Synthesis of pyrimidinyl-substituted alkyne PM74 and conversion into furopyrimidine PM75 and Sonoga...
Scheme 22: Trifluoroacetic acid-promoted conversion of LANCA-derived β-ketoenamides KE into oxazoles OX and 1,...
Scheme 23: Conversion of β-ketoenamide KE79 into oxazole OX16 and transformation into 5-styryl-substituted oxa...
Scheme 24: Mechanisms of the formation of 1,2-diketones DK and of acetyl-substituted oxazole derivatives OX.
Scheme 25: Hydrogenolyses of benzyloxy-substituted β-ketoenamides KE52 and KE54 to 1,2-diketone DK14 and to di...
Scheme 26: Conversions of 2,4-dicyclopropyl-substituted oxazole OX7 into oxazole derivatives OX18–20 (PPA = po...
Scheme 27: Syntheses of vinyl and ethynyl-substituted oxazole derivatives OX21 and OX23 and their palladium-ca...
Scheme 28: Synthesis of C3-symmetric oxazole derivative OX28 and the STM current image of its 1-phenyloctane s...
Scheme 29: Condensation of 1,2-diketones DK with o-phenylenediamine to quinoxalines QU1–7 (CAN = cerium ammoni...
Scheme 30: The LANCA three-component reaction leading to β-ketoenamides KE and the structure of functionalized...
Beilstein J. Org. Chem. 2019, 15, 584–601, doi:10.3762/bjoc.15.54
Graphical Abstract
Figure 1: Cyclopropene-modified mannosamine, glucosamine and galactosamine derivatives employed for MGE.
Figure 2: A) Reaction of ManNCyc and ManNCp, respectively, with Tz-PEG-OH to determine second-order rate cons...
Scheme 1: MGE with cyclopropene-modified mannosamines. Cells were grown with sugar for 48 hours and then incu...
Figure 3: HEK 293T cells were grown with 100 μM Ac4ManNCyc, Ac4ManNCp, Ac4ManNCyoc or DMSO only (negative con...
Scheme 2: Synthesis of Ac4ManNCp(H2) and Ac4ManNCyc(H2) and the corresponding DMB-labeled sialic acids. C/A =...
Scheme 3: Synthesis of Ac4ManNCyoc(H2) and the corresponding DMB-labeled sialic acid.
Scheme 4: Synthesis of Ac4GlcNCp and Ac4GalNCp.
Figure 4: HEK 293T cells were grown with 100 μM Ac4ManNCp, Ac4GlcNCp, Ac4GalNCp or DMSO only (negative contro...
Figure 5: HEK 293T cells were grown with 100 μM Ac4GlcNCp, Ac4GalNCp or DMSO only (negative control) for 48 h...
Figure 6: HEK 293T cells were grown with 50 μM (A) or 100 μM (B) Ac4GlcNCp, Ac4GlcNCyoc or DMSO only (negativ...
Figure 7: Western blot analysis of soluble glycoproteins. HEK 293T cells were grown for 48 h with 100 μM Ac4M...
Scheme 5: Synthesis of Ac4GlcNCp(H2) and Ac4GlcNCyoc(H2).
Beilstein J. Org. Chem. 2019, 15, 535–541, doi:10.3762/bjoc.15.47
Graphical Abstract
Scheme 1: General procedure for the synthesis of nematophin and related derivatives. i) 1.5 equiv α-keto carb...
Scheme 2: Synthesis of azatryptamines (4-azatryptamine (4ATRA) and 1-methyl-4-azatryptamine (1M4ATRA)). i) 5....
Scheme 3: Synthesis of azatryptamines (7-azatryptamine (7ATRA) and 1-methyl-7-azatryptamine (1M7ATRA)). i) 5....
Beilstein J. Org. Chem. 2019, 15, 521–534, doi:10.3762/bjoc.15.46
Graphical Abstract
Scheme 1: Selectivity levels found in multiple multicomponent reactions. I) Innate selectivity; II) sequentia...
Scheme 2: Indiscriminate double Ugi MCR upon pyridine-2,6-dicarboxylic acid.
Scheme 3: Representative examples of MCR-polymer synthesis. A) Biginelli HTS of polymers; B) Passerini;- C) U...
Scheme 4: Concept of multicomponent macrocyclization.
Scheme 5: Supramolecular structures out of MMCR macrocyclizations.
Scheme 6: Macrocyclization by MMCRs. A) Staudinger MCR; B) boronic-imine MCR.
Scheme 7: Selective Sequential MMCRs. A and B) MCRs involving terephthalaldehyde; C) Multiple GBB processes w...
Scheme 8: Biased substrates for selective MMCRs.
Scheme 9: The Union concept. A) Asinger–Ugi combination; B) Passerini–Ugi/azide from anthranilic acid; C) Pas...
Scheme 10: Relevant examples of consecutive MCRs exploiting the Union Concept. A) Petasis-Ugi combination; B) ...
Scheme 11: Selective MMCRs featuring FGs with distinct reactivity along the sequence. A) Synthesis of aminomet...
Scheme 12: High order MMCRs. A) Ugi/Ugi–Smiles 7C combination; B) imidazoline-N-cyanomethylamide-Ugi union lea...
Scheme 13: Consecutive Ugi 4CR-deprotection–Ugi 4CR strategy towards A) PNA oligomers and B) peptidic tetrazol...
Scheme 14: Sequential Ugi 4CR-deprotection access to cyclopeptoids.
Scheme 15: Stepwise access to 6-aminopenicillanic acid derivative through an Asinger, deprotection, Joullié ap...
Scheme 16: A triple MCR-deprotection approach affording anticancer peptidomimetics.
Beilstein J. Org. Chem. 2019, 15, 401–430, doi:10.3762/bjoc.15.36
Graphical Abstract
Figure 1: Structural formulas of Nam, NA, NR+, NMN, and NAD+.
Figure 2: Main synthetic routes to nicotinamide riboside (NR+X−).
Scheme 1: Synthesis of NR+Cl− based on the reaction of peracylated chlorosugars with Nam.
Figure 3: Predominant formation of β-anomer over α-anomer of NR+X−.
Scheme 2: Synthesis of NR+Cl− by reacting 3,5-di-O-benzoyl-D-ribofuranosyl chloride (5) with Nam (1a).
Figure 4: Mechanism of the formation of the β-anomer of the glycosylated product in the case of the reaction ...
Scheme 3: Synthesis of NR+Br− by reacting bromosugars with Nam (1a).
Scheme 4: Synthesis of NR+OTf− based on the glycosylation of Nam (1a) with tetra-O-acetyl-β-D-ribofuranose (2a...
Scheme 5: Improved synthesis of NR+OTfˉ and NAR+OTfˉ based on the glycosylation of pre-silylated Nam or NA wi...
Scheme 6: Synthesis of triacetylated NAR+OTf− by glycosylation of nicotinic acid trimethylsilyl ester with te...
Scheme 7: Synthesis of NR+Cl− from NR+OTf− by means of ion exchange with sodium chloride solution.
Scheme 8: Synthesis of acylated NR+OTf− by means of ion exchange with sodium chloride.
Scheme 9: Synthesis of triacetylated derivatives of NAR+ by glycosylation of nicotinic acid esters with ribos...
Scheme 10: Synthesis of NR+OTf− from the triflate salt of ethyl nicotinate-2,3,5-triacetyl-β-D-riboside in met...
Scheme 11: Reaction of 2,3,5-tri-O-acetyl-β-phenyl nicotinate riboside triflate salt with secondary and tertia...
Scheme 12: Synthesis of NMN based on the Zincke reaction of N-(2,4-dinitrophenyl)-3-carbamoylpyridinium chlori...
Scheme 13: Synthesis of NMN based on the Zincke reaction of N-(2,4-dinitrophenyl)-3-carbamoylpyridinium chlori...
Scheme 14: Efficacious protection of 2′,3′-hydroxy groups of NR+X−.
Scheme 15: Protection of the 2′,3′-hydroxy groups of NR+Cl– with a mesitylmethylene acetal group.
Figure 5: Reduction of derivatives of NR+Xˉ into corresponding 1,2-; 1,4-; 1,6-NRH derivatives.
Figure 6: Mechanism of the reduction of the pyridinium core with dithionite as adapted from [67].
Scheme 16: Reduction of triacylated NR+OTf– derivatives by sodium dithionite followed by complete removal of a...
Figure 7: Structural formulas of iridium and rhodium catalysts (a)–(d) for regeneration of NAD(P)H from NAD(P)...
Figure 8: Two approaches to synthesis of 5′-derivatives of NR+.
Scheme 17: Synthesis of NMN starting from NR+ salt.
Scheme 18: Efficient synthesis of NMN by phosphorylation of 2′,3′-O-isopropylidene-NR+ triflate followed by re...
Scheme 19: Synthesis of a bisphosphonate analogue of β-NAD+ based on DCC-induced conjugation of 2′,3′-O-isopro...
Scheme 20: Synthesis of 5′-acyl and 2′,3′,5′-triacyl derivatives of NR+.
Figure 9: Structural formulas of NMN analogues 39–41.
Scheme 21: Synthesis of 5′-phosphorylated derivatives of NR+ using a “reduction–modification–oxidation” approa...
Scheme 22: Synthesis of 5′-phosphorylated derivatives of NR+ using a “reduction–modification–reoxidation” appr...
Figure 10: Structural formulas of 5′-phosphorylated derivatives of NR+.
Scheme 23: Synthesis of 5′-phosphorylated derivatives of NR+ using a direct NR+ phosphorylation approach.
Figure 11: Structural formulas of amino acid NR+ conjugates.
Scheme 24: Synthesis of amino acid NR+ conjugates using NRH and protected amino acid under CDI-coupling condit...
Figure 12: Chemical structures of known isotopically labelled NR+ analogues and derivatives.
Scheme 25: Synthesis of [2′-3H]-NR+ and [2′-3H]-NMN.
Scheme 26: Synthesis of α- and β-anomers of [1′-2H]-NMN.
Beilstein J. Org. Chem. 2019, 15, 333–350, doi:10.3762/bjoc.15.29
Graphical Abstract
Scheme 1: Representative strategies for the formation of alkylidenecyclopropanes from cyclopropenes and scope...
Scheme 2: [2,3]-Sigmatropic rearrangement of phosphinites 2a–h.
Scheme 3: [2,3]-Sigmatropic rearrangement of a phosphinite derived from enantioenriched cyclopropenylcarbinol...
Scheme 4: Selective reduction of phosphine oxide (E)-3f.
Scheme 5: Attempted thermal [2,3]-sigmatropic rearrangement of phosphinite 6a.
Scheme 6: Computed activation barriers and free enthalpies.
Scheme 7: [2,3]-Sigmatropic rearrangement of phosphinites 6a–j.
Scheme 8: Proposed mechanism for the Lewis base-catalyzed rearrangement of phosphinites 6.
Scheme 9: [3,3]-Sigmatropic rearrangement of tertiary cyclopropenylcarbinyl acetates 10a–c.
Scheme 10: [3,3]-Sigmatropic rearrangement of secondary cyclopropenylcarbinyl esters 10d–h.
Scheme 11: [3,3]-Sigmatropic rearrangement of trichoroacetimidates 12a–i.
Scheme 12: Reaction of trichloroacetamide 13f with pyrrolidine.
Scheme 13: Catalytic hydrogenation of (arylmethylene)cyclopropropane 13f.
Scheme 14: Instability of trichloroacetimidates 21a–c derived from cyclopropenylcarbinols 20a–c.
Scheme 15: [3,3]-Sigmatropic rearrangement of cyanate 27 generated from cyclopropenylcarbinyl carbamate 26.
Scheme 16: Synthesis of alkylidene(aminocyclopropane) derivatives 30–37 from carbamate 26.
Scheme 17: Scope of the dehydration–[3,3]-sigmatropic rearrangement sequence of cyclopropenylcarbinyl carbamat...
Scheme 18: Formation of trifluoroacetamide 50 from carbamate 49.
Scheme 19: Formation of alkylidene[(N-trifluoroacetylamino)cyclopropanes] 51–54.
Scheme 20: Diastereoselective hydrogenation of alkylidenecyclopropane 51.
Scheme 21: Ireland–Claisen rearrangement of cyclopropenylcarbinyl glycolates 56a–l.
Scheme 22: Synthesis and Ireland–Claisen rearrangement of glycolate 61 possessing gem-diester substitution at ...
Scheme 23: Synthesis of alkylidene(gem-difluorocyclopropanes) 66a–h, and 66k–n from propargyl glycolates 64a–n....
Scheme 24: Ireland–Claisen rearrangement of N,N-diBoc glycinates 67a and 67b.
Scheme 25: Diastereoselective hydrogenation of alkylidenecyclopropanes 58a and 74.
Scheme 26: Synthesis of functionalized gem-difluorocyclopropanes 76 and 77 from alkylidenecyclopropane 66a.
Scheme 27: Access to oxa- and azabicyclic compounds 78–80.
Beilstein J. Org. Chem. 2019, 15, 299–309, doi:10.3762/bjoc.15.27
Graphical Abstract
Figure 1: FABMS spectrum (positive mode, NBA matrix) of cichorinotoxin over the mass range of m/z 150─1000.
Figure 2: The segment identified based on the FABMS spectrum (peptide fragment b ions).
Figure 3: NMR analyses of the segment consisting of 3-hydroxydecanoyl-dehydrothreonin-proline (600 MHz, aceto...
Figure 4: Key NMR observations used to construct the backbone sequence.
Figure 5: Fragment obtained by acid hydrolysis and each amino acid was exclusively D-configuration (peptide f...
Figure 6: The complete structure of cichorinotoxin monoacetate and the assignments of 1H NMR chemical shifts,...
Figure 7: Determination of the positions of the acetyl groups in the tetraacetate.
Figure 8: Partial structure of compound A as deduced from its NOE data; key NOEs are represented by double-he...
Figure 9: Partial structure of compound B (Val16 to Val22 residues). The chemical shifts (δH and δC (ppm)) ar...
Figure 10: Mechanism of the formation of compounds A and B from cichorinotoxin by alkaline hydrolysis.
Beilstein J. Org. Chem. 2019, 15, 236–255, doi:10.3762/bjoc.15.22
Graphical Abstract
Figure 1: Structure of L-glutamic acid.
Figure 2: 3-Hydroxy- (2), 4-hydroxy- (3) and 3,4-dihydroxyglutamic acids (4).
Figure 3: Enantiomers of 3-hydroxyglutamic acid (2).
Scheme 1: Synthesis of (2S,3R)-2 from (R)-Garner's aldehyde. Reagents and conditions: a) MeOCH=CH–CH(OTMS)=CH2...
Scheme 2: Synthesis of (2S,3R)-2 and (2S,3S)-2 from (R)-Garner’s aldehyde. Reagents and conditions: a) H2C=CH...
Scheme 3: Two-carbon homologation of the protected L-serine. Reagents and conditions: a) Fmoc-succinimide, Na2...
Scheme 4: Synthesis of di-tert-butyl ester of (2R,3S)-2 from L-serine. Reagents and conditions: a) PhSO2Cl, K2...
Scheme 5: Synthesis of (2R,3S)-2 from O-benzyl-L-serine. Reagents and conditions: a) (CF3CH2O)2P(O)CH2COOMe, ...
Scheme 6: Synthesis of (2S,3R)-2 employing a one-pot cis-olefination–conjugate addition sequence. Reagents an...
Scheme 7: Synthesis of the orthogonally protected (2S,3R)-2 from a chiral aziridine. Reagents and conditions:...
Scheme 8: Synthesis of N-Boc-protected (2S,3R)-2 from D-phenylglycine. Reagents and conditions: a) BnMgCl, et...
Scheme 9: Synthesis of (2S,3R)-2 employing ketopinic acid as chiral auxiliary. Reagents and conditions: a) Br2...
Scheme 10: Synthesis of dimethyl ester of (2S,3R)-2 employing (1S)-2-exo-methoxyethoxyapocamphane-1-carboxylic...
Scheme 11: Synthesis of N-Boc-protected dimethyl ester of (2S,3R)-2 from (S)-N-(1-phenylethyl)thioacetamide. R...
Scheme 12: Synthesis of N-Boc-protected dimethyl ester of (2S,3R)-2 via Sharpless epoxidation. Reagents and co...
Scheme 13: Synthesis of (2S,3S)-2 from the imide 51. Reagents and conditions: a) NaBH4, MeOH/CH2Cl2; b) Ac2O, ...
Scheme 14: Synthesis of (2R,3S)-2 and (2S,3S)-2 from the acetolactam 55 (PMB = p-methoxybenzyl). Reagents and ...
Scheme 15: Synthesis of (2S,3R)-2 from D-glucose. Reagents and conditions: a) NaClO2, 30% H2O2, NaH2PO4, MeCN;...
Figure 4: Enantiomers of 3-hydroxyglutamic acid (3).
Scheme 16: Synthesis of (4S)-4-hydroxy-L-glutamic acid [(2S,4S)-3] by electrophilic hydroxylation. Reagents an...
Scheme 17: Synthesis of all stereoisomers of 4-hydroxyglutamic acid (3). Reagents and conditions: a) Br2, PBr5...
Scheme 18: Synthesis of the orthogonally protected 4-hydroxyglutamic acid (2S,4S)-73. Reagents and conditions:...
Scheme 19: Synthesis of (2S,4R)-4-acetyloxyglutamic acid as a component of a dipeptide. Reagents and condition...
Scheme 20: Synthesis of N-Boc-protected dimethyl esters of (2S,4R)- and (2S,4S)-3 from (2S,4R)-4-hydroxyprolin...
Scheme 21: Synthesis of orthogonally protected (2S,4S)-3 from (2S,4R)-4-hydroxyproline. Reagents and condition...
Scheme 22: Synthesis of the protected (4R)-4-hydroxy-L-pyroglutamic acid (2S,4R)-87 by electrophilic hydroxyla...
Figure 5: Enantiomers of 3,4-dihydroxy-L-glutamic acid (4).
Scheme 23: Synthesis of (2S,3S,4R)-4 from the epoxypyrrolidinone 88. Reagents and conditions: a) MeOH, THF, KC...
Scheme 24: Synthesis of (2S,3R,4R)-4 from the orthoester 92. Reagents and conditions: a) OsO4, NMO, acetone/wa...
Scheme 25: Synthesis of (2S,3S,4S)-4 from the aziridinolactone 95. Reagents and conditions: a) BnOH, BF3·OEt2,...
Scheme 26: Synthesis of (2S,3S,4R)-4 and (2R,3S,4R)-4 from cyclic imides 106. Reagents and conditions: a) NaBH4...
Scheme 27: Synthesis of (2R,3R,4R)-4 and (2S,3R,4R)-4 from the cyclic meso-imide 110. Reagents and conditions:...
Scheme 28: Synthesis of (2S,3S,4S)-4 from the protected serinal (R)-23. Reagents and conditions: a) Ph3P=CHCOO...
Scheme 29: Synthesis of (2S,3S,4S)-4 from O-benzyl-N-Boc-D-serine. Reagents and conditions: a) ClCOOiBu, TEA, ...
Scheme 30: Synthesis of (2S,3S,4R)-127 by enantioselective conjugate addition and asymmetric dihydroxylation. ...
Figure 6: Structures of selected compounds containing hydroxyglutamic motives (in blue).
Beilstein J. Org. Chem. 2019, 15, 187–193, doi:10.3762/bjoc.15.18
Graphical Abstract
Scheme 1: Methylation of HHQ (1).
Scheme 2: Synthesis of methylated HQNO derivatives.
Scheme 3: Synthesis of methylated PQS derivatives.
Figure 1: Overview of AQ compounds (A), and effect of AQs on the growth of S. aureus Newman (B). 24-Well plat...
Figure 2: Inhibition of cellular O2 consumption rate (cOCR) of S. aureus Newman. Cell suspensions (OD600 nm o...
Figure 3: Impact on AQ quorum sensing by the newly synthesized AQ derivatives. Cultures of P. aeruginosa PAO1...